NASDAQ$MURA
Mural Oncology Plc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Mural Oncology announced its financial results for Q4 2023 and provided a business update.
Mural Oncology reported a net loss of $59.5 million for the fourth quarter of 2023. As of December 31, 2023, cash and cash equivalents were $270.9 million. The company expects its cash resources to fund operations into the fourth quarter of 2025.
- Mural Oncology became an independent company in November 2023.
- The company plans to evaluate the LFIV nemvaleukin dosing regimen in cohort 3 of ARTISTRY-6.
- Enrollment is ongoing for ARTISTRY-6 and ARTISTRY-7.
- Mural Oncology intends to nominate development candidates for IL-18 and IL-12 therapies in 2024.
Headline financials
Revenue & EPS history
Mural Oncology · Revenue · Quarterly
$2.62M
Forward guidance
Mural Oncology expects its cash resources to fund its operations into the fourth quarter 2025 and anticipates reporting lower operating expenses in the quarters going forward.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports · overlaid with Q4 2023
-9.3%
Avg return
Earnings day
-9.4%
Avg return
5 days after
+5.1%
Avg return
30 days after
23%
3 / 13 earnings
Positive
+14.6%
Q4 2023
Best reaction
-61.6%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -0.5% | -0.5% | — | |
| Q2 2025 | -20.2% | -30.3% | -9.2% | |
| Q1 2025 | -4.4% | -4.7% | -10.9% | |
| Q4 2024 | -61.6% | -65.0% | -31.3% | |
| Q3 2024 | -0.9% | -4.8% | +2.3% | |
| Q2 2024 | +1.0% | +4.5% | +0.6% | |
| Q1 2024 | +2.7% | +4.0% | -12.0% | |
| Q4 2023 | +14.6% | +13.2% | -16.7% | |
| Q1 2023 | -10.4% | -7.7% | +27.7% | |
| Q2 2023 | -10.4% | -7.7% | +27.7% | |
| Q3 2022 | -10.4% | -7.7% | +27.7% | |
| Q4 2022 | -10.4% | -7.7% | +27.7% | |
| Q3 2023 | -10.4% | -7.7% | +27.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro